|
|
|
|
 Rita Theodotou,
Director, Global Oncology Bayer Healthcare Rita Theodotou built and directs the Oncology Scientific Relations function driving scientific relations and marketing operations for Bayer Global Oncology with global revenues of EURO 650 million. Reporting directly to the Vice President, Global Oncology Marketing, responsible for global medical marketing of the late stage agent oncology portfolio which includes 3 agents and 10 indications, through close collaboration with the commercial and medical affairs functions. Rita built and manages a team of 5 direct reports, 4 external medical education agencies and a strategic team of 10 key country and regional marketing directors.
Rita studied at University Of South Carolina gaining a M.Sc., Business Administration in Marketing and Marketing Research (FULLBRIGHT SCHOLAR, 1984-1988) and a B.Sc., Business Administration in Marketing and Management Science.
She has also authored Scientific Publications including ‘Recognition of depressive programs in the elderly: what can help the patient and the doctor’ (Authors: Ioannis A Parashos, Sophia Stamouli, Efi Rogakou, Rita Theodotou, Ioannis Nikas, Athanasios Mougias) and ‘The problem of non-compliance in schizophrenia: Opinions of patients and their relatives. A pilot study’ (Authors: Ioannis A Parashos; Konstantinos Xiromeritis; Vassiliki Zoumbou; Sophia Stamouli; Rita Theodotou)
Appearing: DAY 1 TUESDAY 21 SEPTEMBER – REGULATION & REIMBURSEMENT IN EUROPE 2.10pm Product marketing: a new approach
- The strategy: advocating physicians in emerging economies by leveraging the expertise of physicians in developed countries.
- Commercial implications: identifying high volume prescribing centres, promoting the product through a new treatment paradigm and improving relationships with world health authorities.
- What has this unique approach achieved to date, and how will it stimulate the market for targeted cancer therapies in the coming decade?
Rita Theodotou, Director, Global Oncology,
Bayer Healthcare 2.40pm Panel discussion: improving targeted cancer therapy patient access
- What are the main concerns for market access to targeted therapies for cancer? Considering payers, prescribers and patients.
- How can companies work more closely with patients to improve market access?
- Developing innovative and holistic approaches to solving TCT access challenges: what is the way forward?
Rita Theodotou, Director, Global Oncology,
Bayer Healthcare DAY 2 WEDNESDAY 22 SEPTEMBER – IMPROVING PRE-CLINICAL & EARLY DEVELOPMENT 12.40pm Case study: a complex immunohistochemical, molecular, and FISH analysis to guide therapy for non-small cell lung adenocarcinoma
- What are the options for a pathologist using immunohistochmical and molecular tests to select appropriate drugs for first line chemotherapy?
- What are the options for a pathologist using an algorithmic array of molecular tests to detect targets for appropriate second line biological therapy?
- Future approaches to refine and expand predictive analysis of non-small lung adenocarcinoma – what is required from the perspective of a pathologist?
Rita Theodotou, Director, Global Oncology,
Bayer Healthcare Corporate Affairs Director,
Eli Lilly France |
|
|
|
|
Conference:
Day 1
September 21, 8:30am - 5:30pm
Day 2
September 22, 8:30am - 5:30pm
Day 3
September 23, 9am - 5:30pm
|
|
|
|
|
|
|
|
|
